Until 2025, the semaglutide vs tirzepatide comparison depended on indirect comparisons between separate trials — an imperfect methodology given different study populations, follow-up durations, and definitions of outcome. SURMOUNT-5 changed that. Published in 2025, this direct head-to-head randomized controlled trial (N=751, tirzepatide 15mg vs semaglutide 2.4mg weekly, 72 weeks, in adults with obesity without type 2 diabetes) produced a clear result: tirzepatide produced 20.2% total body weight loss vs 13.7% with semaglutide — a 47% greater absolute weight loss. Tirzepatide also outperformed on waist circumference, body fat percentage, and metabolic parameters.
The mechanism explanation for this difference is biologically coherent. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP+GLP-1 receptor agonist — the first approved drug in this class. GIP (glucose-dependent insulinotropic polypeptide) was historically considered the "forgotten incretin" because GIP resistance seemed to develop in type 2 diabetes. But pharmacological GIP receptor agonism — at doses much higher than physiological — produces metabolic benefits that are additive or synergistic with GLP-1R agonism. The combination suppresses appetite more deeply, with paradoxically lower GI side effects (tirzepatide has lower nausea and vomiting rates than semaglutide despite greater weight loss — likely because GIP agonism counteracts some of GLP-1's emetic effects).
| Parameter | Semaglutide (Wegovy 2.4mg) | Tirzepatide (Zepbound 15mg) |
|---|---|---|
| Mechanism | GLP-1R agonist only | Dual GIP+GLP-1R agonist |
| Weight loss (pivotal trial) | -14.9% (STEP 1, 68 wks) | -20.9% (SURMOUNT-1, 72 wks, 15mg) |
| Weight loss (head-to-head) | -13.7% (SURMOUNT-5, 72 wks) | -20.2% (SURMOUNT-5, 72 wks) |
| Nausea rate | 44% (STEP 1) | 31% (SURMOUNT-1, 15mg) |
| Vomiting rate | 24% (STEP 1) | 16% (SURMOUNT-1, 15mg) |
| CV outcomes trial | SELECT (N=17,604): -20% MACE ✅ confirmed | SURMOUNT-CVOT: ongoing as of 2025 |
| T2D indication | Ozempic (0.5–2mg weekly) | Mounjaro (2.5–15mg weekly) |
| Obesity indication | Wegovy (2.4mg weekly) | Zepbound (2.5–15mg weekly) |
| US list price (2025) | ~$1,300–1,500/month | ~$1,100–1,300/month |
| Half-life / dosing | ~1 week / once weekly | ~5 days / once weekly |
| Pancreatitis warning | Black box (same for both) | Black box (same for both) |
| Pregnancy | Contraindicated — stop 2 months before conception | Contraindicated — stop 2 months before conception |
| Patient Profile | Preferred Drug | Rationale |
|---|---|---|
| Obesity without T2D, maximum weight loss priority | Tirzepatide | SURMOUNT-5: 47% greater weight loss |
| Established cardiovascular disease (prior MI, stroke) | Semaglutide | SELECT trial: proven -20% MACE reduction; tirzepatide CVOT not completed |
| T2D + obesity, primary goal glycemic control | Tirzepatide (Mounjaro) | SURPASS trials: superior HbA1c reduction vs semaglutide; FDA-approved for T2D |
| Significant nausea on GLP-1 drugs previously | Tirzepatide | Lower GI side effect rates despite higher efficacy |
| Insurance covers only one option | Whichever is covered | Access > marginal efficacy difference in most cases |
| PCOS with insulin resistance | Semaglutide or tirzepatide | Semaglutide: HARMONIA trial data; tirzepatide: mechanistic rationale, trials ongoing |